Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | APOB | P04114 | 1/20 | 0.40 |
| ▸ | MTTP | P55157 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789164 | 0.90 | TP53 (0.45) | TP53LMNAAPOBMTTPPOLB | |
| SCHEMBL6491198 | 0.86 | APOB (0.39) | TP53LMNAAPOBMTTPPOLB | |
| SCHEMBL6488310 | 0.86 | SMN1; SMN2 (0.51) | TP53LMNAAPOBMTTPPOLB | |
| SCHEMBL6492604 | 0.86 | MTTP (0.42) | TP53APOBMTTPPOLBMAPT | |
| SCHEMBL6492199 | 0.86 | TP53 (0.46) | TP53LMNAAPOBMTTPPOLB | |
| SCHEMBL6501863 | 0.84 | SMN1; SMN2 (0.43) | LMNAPOLBMAPTRXFP1GCGR | |
| SCHEMBL6680191 | 0.83 | LMNA (0.38) | TP53LMNAPOLBSREBF2MAPT | |
| SCHEMBL6646880 | 0.82 | RXFP1 (0.37) | TP53SREBF2MAPTRXFP1NPC1 | |
| SCHEMBL6500248 | 0.82 | APOB (0.45) | TP53LMNAAPOBMTTPPOLB | |
| SCHEMBL6499119 | 0.81 | TP53 (0.45) | TP53LMNAPOLBSREBF2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | TP53 3031/4885LMNA 629/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.